Nasdaq:US$15.05 (-0.05) | HKEX:HK$23.55 (-0.20) | AIM:£2.27 (+0.08)
Search
Announcements
1
2
34567891011121314151617
found Documents: 845
Announcements & Press Releases, Oncology / Immunology | 22 Nov 2024

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the United States,
Read More
LSE RNS Announcemnet (PDF)HKEX Annoucement (PDF)
Announcements & Press Releases, Regulatory Notice | 21 Nov 2024

List of Directors and Their Roles and Functions
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 20 Nov 2024

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, November 20, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independen
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 6 Nov 2024

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, November 6, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as severa
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Nov 2024

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Oct 2024

Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ — Thursday, October 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at October 31, 2024, the issued share capital of HUTCHMED consisted o
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 31 Oct 2024

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer — Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today a
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 21 Oct 2024

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ — Monday, October 21, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on O
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 16 Oct 2024

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
 — New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer — — MET is a common biomarker in this setting for patients who develop resistance to EGFR targeted therapies
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 3 Oct 2024

HUTCHMED’s ELUNATE® (fruquintinib) Listed with Full Subsidy in the Hong Kong Hospital Authority Drug Formulary
— First innovative oncology medicine ever to get enlisted in HA Drug Formulary directly under the Special Drug category — — First new drug approved by 1+ Mechanism listed in the Hospital Authority Drug Formulary — — Rapid enlistment and
Read More
View Press Release (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Oct 2024

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 24 Sep 2024

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — — Fruquintinib already approved in several regions including the United States, Europe and China —  
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 10 Sep 2024

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
Hong Kong, Shanghai & Florham Park, NJ — Monday, September 9, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be p
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Sep 2024

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 30 Aug 2024

Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ — Friday, August 30, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at August 30, 2024, the issued share capital of HUTCHMED consisted of 87
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 30 Aug 2024

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
Hong Kong, Shanghai & Florham Park, NJ — Friday, August 30, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA”) in C
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 22 Aug 2024

TR-1: Standard form for notification of major holdings
 TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlyi
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 21 Aug 2024

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, August 21, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a physician expert call with a professor and key opinion leader in immune
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Interim Reports, Regulatory Notice | 15 Aug 2024

Interim Report 2024
2024 Interim ReportNotification letter to non-registered shareholders and request form: Notice of Publication of 2024 Interim ReportNotification letter to registered shareholders and request form: Notice of Publication of 2024 Interim Report2024 Interim Report (Chinese version)
Regulatory Notice | 6 Aug 2024

Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Aug 2024

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Aug 2024

List of Directors and Their Roles and Functions
HKEX Announcement (PDF)
Announcements & Press Releases, Group | 31 Jul 2024

HUTCHMED Reports 2024 Interim Results and Provides Business Updates
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, July 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:​HCM; HKEX:​13) today reports its financial results for the six months ended June 30, 20
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 4 Jul 2024

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 4, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of adult pat
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 Jul 2024

Monthly Return
HKEX Announcement (PDF)
Regulatory Notice | 28 Jun 2024

Overseas regulatory announcements: Filing of Form F-3
Hong Kong, Shanghai & Florham Park, NJ: Friday, June 28, 2024: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today filed the Form F-3 Registration Statement with the U.S. Securities and Exchange Commission.  This filing follow
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)Form F-3
Announcements & Press Releases, Regulatory Notice | 28 Jun 2024

Blocklisting Six Monthly Return
Hong Kong, Shanghai, & Florham Park, NJ — Friday, June 28, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:   1. Name of
Read More
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 28 Jun 2024

Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ — Friday, June 28, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at June 28, 2024, the issued share capital of HUTCHMED consisted of 871,35
Read More
HKEX Announcement (PDF)
Announcements & Press Releases, Group, Regulatory Notice | 26 Jun 2024

HUTCHMED to Announce 2024 Half-Year Financial Results
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, June 26, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 24 Jun 2024

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
— HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 —   Hong Kong, Shanghai & Florham Park, NJ —  Monday, June 24, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today an
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 22 Jun 2024

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZAQLA® (fruquintinib) is the first novel targeted therapy in the EU for metastatic colorectal cancer regard
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 17 Jun 2024

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of therapies or prior TPO/TPO-RA[1
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 7 Jun 2024

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
Hong Kong, Shanghai & Florham Park, NJ — Friday, June 7, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hem
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Jun 2024

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 3 Jun 2024

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024   Hong Kong, Shanghai & Florham Park, NJ — Monday, June 3, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) to
Read More
HKEX Announcement (PDF)LSE RNS Announcemnet (PDF)
Announcements & Press Releases, Regulatory Notice | 31 May 2024

Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ — Friday, May 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at May 31, 2024, the issued share capital of HUTCHMED consisted of 871,264,
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 24 May 2024

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
Hong Kong, Shanghai & Florham Park, NJ — Friday, May 24, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presen
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 17 May 2024

List of Directors and Their Roles and Functions
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 17 May 2024

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
Hong Kong, Shanghai & Florham Park, NJ  — Friday, May 17, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces:- the retirement of Mr Simon To from the position as Chairman a
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 May 2024

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
Hong Kong, Shanghai & Florham Park, NJ — Friday, May 17, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM‑01 Phase III study of sovleplenib, as well as
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcement Topics, Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 May 2024

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s surufatinib and anti-PD-1 activity with Hengr
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 14 May 2024

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, May 14, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306 in patients with mut
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 13 May 2024

List of Directors and Their Roles and Functions
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 10 May 2024

Annual General Meeting held on May 10, 2024 – Poll Results
Hong Kong, Shanghai, & Florham Park, NJ: Friday, May 10, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and the special resolution put to its Annual Ge
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 8 May 2024

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees
Hong Kong, Shanghai & Florham Park, NJ  — Wednesday, May 8, 2024: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Dr Renu Bhatia is appointed as an Independent Non-executive D
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 May 2024

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 26 Apr 2024

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO‑2 Phase III clinic
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 22 Apr 2024

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ — Monday, April 22, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on Apr
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Event, Regulatory Notice | 8 Apr 2024

Annual General Meeting 2024
Date: Friday, May 10, 2024 Time: 5:00 pm Hong Kong Time (10:00 am London Time) Location:1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom, Kowloon, Hong Kong  
Read More
2023 Annual Report (PDF)2023 Sustainability Report (PDF)Circular - Annual General Meeting (PDF)Announcement - Notice of Annual General Meeting (PDF)Form of Proxy (PDF)Notification letter to registered holders and request form (PDF)Notification letter to non-registered holders and request form (PDF)Online AGM User Guide (PDF)
Announcements & Press Releases, Regulatory Notice | 8 Apr 2024

2023 Annual Report and Notice of Annual General Meeting
Hong Kong, Shanghai, & Florham Park, NJ — Monday, April 8, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2023 Annual Report, together with the Notice of Annual General Meeting and the Form
Read More
LSE RNS Announcement (PDF)HKEX Overseas Regulatory Announcement (PDF)HKEX Announcement – Notice of Annual General Meeting (PDF)
1
2
34567891011121314151617